Annexon, Inc. (NASDAQ:ANNX) Receives $15.80 Consensus Target Price from Analysts

Annexon, Inc. (NASDAQ:ANNX) has been assigned a consensus rating of “Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year is $15.80.

ANNX has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th.

Institutional Investors Weigh In On Annexon

Several institutional investors have recently added to or reduced their stakes in ANNX. BNP Paribas Financial Markets bought a new stake in shares of Annexon in the fourth quarter valued at approximately $59,000. CANADA LIFE ASSURANCE Co purchased a new position in Annexon in the 4th quarter valued at approximately $77,000. E Fund Management Co. Ltd. boosted its holdings in shares of Annexon by 36.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Forefront Analytics LLC boosted its holdings in shares of Annexon by 56.8% in the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock worth $84,000 after acquiring an additional 5,950 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Annexon in the fourth quarter valued at $98,000.

Annexon Price Performance

ANNX opened at $2.83 on Friday. Annexon has a fifty-two week low of $2.63 and a fifty-two week high of $8.40. The company’s 50-day moving average is $4.29 and its 200 day moving average is $5.57. The firm has a market capitalization of $301.65 million, a P/E ratio of -2.70 and a beta of 1.07.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.